Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ernexa Therapeutics Inc.BTX · Entity 8278 | Director · CEO & President | March 11, 2022 | March 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ernexa Therapeutics Inc.
Report date March 11, 2022 · Filed March 18, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2032-03-11 | Direct | 413,700 |
Reported balance
After 2022-03-11 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2022-03-11 · Grant · Acquired 413,700 · Balance 413,700 F1: The options vest and become exercisable in 36 substantially equal monthly installments from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable in 36 substantially equal monthly installments from the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2022 Filed Mar 16, 2022 01:34 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 413,700 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-22-009662 · form4.xml · derivative · entry 1 Federoff Howard J. · CIK 0001857261 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,700 Underlying: Common Stock · 413,700 shares Expires 2032-03-11 F1 · derivative.exercise_date: The options vest and become exercisable over three years, with 25% of the options vesting on the one-year anniversary of the grant date and the remaining options vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 11, 2022 Filed Mar 18, 2022 01:00 UTC Amendment | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 413,700 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-22-009982 · form4.xml · derivative · entry 1 Federoff Howard J. · CIK 0001857261 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,700 Underlying: Common Stock · 413,700 shares Expires 2032-03-11 F1 · derivative.exercise_date: The options vest and become exercisable in 36 substantially equal monthly installments from the grant date. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 00:16 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option · Derivative | 597,253 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001140361-21-013551 · form4.xml · derivative · entry 2 Federoff Howard J. · CIK 0001857261 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,253 Underlying: Common Stock · 597,253 shares Expires 2031-04-15 F2 · derivative.exercise_date: The option vests and becomes exercisable in full upon the occurrence of the first approval by the Food and Drug Administration of an investigational new drug application in connection with that certain license among the Issuer, Factor Biosciences Therapeutics Limited and Novellus Therapeutics Limited, subject to continued service through such vesting date. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 00:16 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option · Derivative | 2,627,915 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001140361-21-013551 · form4.xml · derivative · entry 1 Federoff Howard J. · CIK 0001857261 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,627,915 Underlying: Common Stock · 2,627,915 shares Expires 2031-04-15 F1 · derivative.exercise_date: The option vests and becomes exercisable over four years, with 656,979 shares vesting on April 16, 2022, 54,748 shares vesting on the sixteenth day of each month from May 2022 through March 2025, and the remaining 54,756 shares vesting on April 16, 2025, subject to continued service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.